By Colin Kellaher

Johnson & Johnson's Janssen Pharmaceutical Cos. unit on Tuesday said a Phase 2b study of its respiratory syncytial virus adult vaccine candidate met all endpoints.

Janssen said the vaccine candidate was highly effective in protecting against three clinical definitions of lower respiratory tract disease caused by RSV, showing vaccine efficacy of 70% to 80% in adults ages 65 and older.

The company said the vaccine candidate was also shown to be generally well-tolerated.

Janssen said that based on the positive results from the Phase 2b study, it has initiated a global Phase 3 trial, adding that there are currently no approved vaccines or broadly indicated antivirals available, leaving older adults at high risk of developing potentially life-threatening illness from RSV.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

December 07, 2021 07:16 ET (12:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.
Johnson and Johnson (NYSE:JNJ)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024 Haga Click aquí para más Gráficas Johnson and Johnson.